The Impact of Adding Nivolumab to First-Line Chemotherapy in Patients with Advanced Gastric Cancer
Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer. However, real-world data on the efficacy of Nivo-Chemo are limited. In this MEDtalk, Dr. Mai Utsumi presents a study on the impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.
Få tillgång
Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.
- Få tillgång
- Om du redan har en profil: Logga in
